Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia

D. Dlouha, M. Blaha, P. Huckova, V. Lanska, JA. Hubacek, V. Blaha

. 2023 ; 14 (8) : . [pub] 20230801

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23016630

Lipoprotein apheresis (LA) is a therapeutic option for patients with severe hypercholesterolemia who have persistently elevated LDL-C levels despite attempts at drug therapy. MicroRNAs (miRNAs), important posttranscriptional gene regulators, are involved in the pathogenesis of atherosclerosis. Our study aimed to monitor the dynamics of twenty preselected circulating miRNAs in patients under long-term apheresis treatment. Plasma samples from 12 FH patients (men = 50%, age = 55.3 ± 12.2 years; mean LA overall treatment time = 13.1 ± 7.8 years) were collected before each apheresis therapy every sixth month over the course of four years of treatment. Eight complete follow-up (FU) samples were measured in each patient. Dynamic changes in the relative quantity of 6 miRNAs (miR-92a, miR-21, miR-126, miR-122, miR-26a, and miR-185; all p < 0.04) during FU were identified. Overall apheresis treatment time influenced circulating miR-146a levels (p < 0.04). In LDLR mutation homozygotes (N = 5), compared to heterozygotes (N = 7), we found higher plasma levels of miR-181, miR-126, miR-155, and miR-92a (all p < 0.03). Treatment with PCSK9 inhibitors (N = 6) affected the plasma levels of 7 miRNAs (miR-126, miR-122, miR-26a, miR-155, miR-125a, miR-92a, and miR-27a; all p < 0.04). Long-term monitoring has shown that LA in patients with severe familial hypercholesterolemia influences plasma circulating miRNAs involved in endothelial dysfunction, cholesterol homeostasis, inflammation, and plaque development. The longer the treatment using LA, the better the miRNA milieu depicting the potential cardiovascular risk.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016630
003      
CZ-PrNML
005      
20231026105651.0
007      
ta
008      
231013s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/genes14081571 $2 doi
035    __
$a (PubMed)37628623
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Dlouha, Dana $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $1 https://orcid.org/0000000171671336
245    10
$a Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia / $c D. Dlouha, M. Blaha, P. Huckova, V. Lanska, JA. Hubacek, V. Blaha
520    9_
$a Lipoprotein apheresis (LA) is a therapeutic option for patients with severe hypercholesterolemia who have persistently elevated LDL-C levels despite attempts at drug therapy. MicroRNAs (miRNAs), important posttranscriptional gene regulators, are involved in the pathogenesis of atherosclerosis. Our study aimed to monitor the dynamics of twenty preselected circulating miRNAs in patients under long-term apheresis treatment. Plasma samples from 12 FH patients (men = 50%, age = 55.3 ± 12.2 years; mean LA overall treatment time = 13.1 ± 7.8 years) were collected before each apheresis therapy every sixth month over the course of four years of treatment. Eight complete follow-up (FU) samples were measured in each patient. Dynamic changes in the relative quantity of 6 miRNAs (miR-92a, miR-21, miR-126, miR-122, miR-26a, and miR-185; all p < 0.04) during FU were identified. Overall apheresis treatment time influenced circulating miR-146a levels (p < 0.04). In LDLR mutation homozygotes (N = 5), compared to heterozygotes (N = 7), we found higher plasma levels of miR-181, miR-126, miR-155, and miR-92a (all p < 0.03). Treatment with PCSK9 inhibitors (N = 6) affected the plasma levels of 7 miRNAs (miR-126, miR-122, miR-26a, miR-155, miR-125a, miR-92a, and miR-27a; all p < 0.04). Long-term monitoring has shown that LA in patients with severe familial hypercholesterolemia influences plasma circulating miRNAs involved in endothelial dysfunction, cholesterol homeostasis, inflammation, and plaque development. The longer the treatment using LA, the better the miRNA milieu depicting the potential cardiovascular risk.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a proproteinkonvertasa subtilisin/kexin typu 9 $x genetika $7 D000071449
650    12
$a cirkulující mikroRNA $x genetika $7 D000074166
650    12
$a separace krevních složek $7 D001781
650    12
$a mikro RNA $x genetika $7 D035683
650    12
$a hyperlipoproteinemie typ II $x genetika $x terapie $7 D006938
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Blaha, Milan $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Králové, 50005 Hradec Králové, Czech Republic $u Faculty of Medicine in Hradec Králové, Charles University, 50003 Hradec Králové, Czech Republic
700    1_
$a Huckova, Pavlina $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $1 https://orcid.org/0000000167554786
700    1_
$a Lanska, Vera $u Statistical Unit, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic
700    1_
$a Hubacek, Jaroslav Alois $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u 1st Faculty of Medicine, Charles University, 12108 Prague, Czech Republic $1 https://orcid.org/0000000165371353
700    1_
$a Blaha, Vladimir $u Faculty of Medicine in Hradec Králové, Charles University, 50003 Hradec Králové, Czech Republic $u 3rd Department of Internal Medicine-Metabolism and Gerontology, University Hospital Hradec Králové, 50005 Hradec Králové, Czech Republic $1 https://orcid.org/0000000180889919 $7 xx0002944
773    0_
$w MED00174652 $t Genes $x 2073-4425 $g Roč. 14, č. 8 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37628623 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105645 $b ABA008
999    __
$a ok $b bmc $g 2000258 $s 1202992
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 14 $c 8 $e 20230801 $i 2073-4425 $m Genes $n Genes $x MED00174652
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Archiving options